NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

NCT02348255 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor Accrual

Conditions

Adult Brain Glioblastoma
Recurrent Adult Brain Neoplasm

Interventions

PROCEDURE: Electric Field Therapy
BIOLOGICAL: Bevacizumab
DRUG: Carmustine
OTHER: Quality-of-Life Assessment

Sponsor

University of California, Davis

Collaborators

[object Object]
[object Object]